The WHO Emergency Committee recently acknowledged that some progress had been made in the global response to the multi-country outbreak of monkeypox since the last meeting.
The Committee held the consensus view on November 1, 2022, that the event continues to meet the criteria for a Public Health Emergency of International Concern and highlights the primary reasons for ongoing concern.
These include an emerging potential for more significant health impact in vulnerable populations, continuing risk of stigma and discrimination, and other outbreak gaps.
HIV and Monkeypox Combo Remain Global Concern
Europe Approves Single-dose RSV Option for Infants
The European Commission became the first regulatory body to approve preventing respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season with passive immunization.
AstraZeneca and Sanofi’s Beyfortus® (nirsevimab) approval in the European Union was announced on November 4, 2022.
However, the actual availability date in Europe was not disclosed today.
Pfizer Study Reveals Big Rise in Immunity From COVID-19 Booster
FDA says findings affirm its decision to approve the booster without human testing based on experience with a similarly tweaked vaccine
Age-Adjusted Rate of Alcohol-Induced Deaths Up From 2019 to 2020
Rates of alcohol-induced deaths in 2020 increased with age, peaking for those aged 55 to 64 years